Nureca Ltd

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trend, and technical outlook.

Nureca Ltd, a micro-cap player in the healthcare services sector, has seen its valuation parameters deteriorate significantly, with its price-to-earnings (P/E) ratio soaring to 109.5 and price-to-book value (P/BV) hovering at 1.15. This shift from an expensive to a risky valuation grade coincides with a steep 14.85% drop in its share price on 2 June 2026, signalling growing investor concerns amid underwhelming financial performance and challenging market conditions.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd., a micro-cap home healthcare and wellness products company with a market capitalisation of ₹268.00 crores, reported a concerning fourth quarter for FY26, posting a net loss of ₹6.09 crores compared to a profit of ₹3.73 crores in the previous quarter—a dramatic reversal that has raised red flags amongst investors. The stock, trading at ₹280.90 as of May 29, 2026, remains under pressure despite a modest 1.78% gain in the most recent trading session, reflecting broader concerns about the company's operational sustainability and profitability trajectory.

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 27 Apr 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent challenges in its long-term fundamentals and valuation metrics. The upgrade is primarily driven by improvements in technical indicators, while financial trends and quality scores remain mixed, prompting a cautious stance among investors.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 20 Apr 2026. This shift reflects deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamental trends despite recent positive quarterly financial results.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent challenges in its fundamental financial metrics. The upgrade is driven primarily by improvements in technical indicators, while valuation and financial trends present a mixed picture for investors.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 April 2026. This shift reflects a confluence of deteriorating technical indicators, an expensive valuation profile, weak financial trends, and subpar quality metrics. The downgrade comes despite the company’s recent positive quarterly results, underscoring growing concerns about its longer-term fundamentals and market positioning.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently formed a Death Cross, a technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.

Nureca Ltd, a micro-cap player in the healthcare services sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. Despite a recent day gain of 5.87%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical and peer averages, raising questions about its price attractiveness amid subdued returns and deteriorating profitability metrics.

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 227.42, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nureca Ltd locked at its upper circuit of 10% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Nureca Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 Mar 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its valuation metrics shift notably, with its price-to-earnings (P/E) ratio rising to 21.57 and price-to-book value (P/BV) inching up to 1.15. This movement has prompted a downgrade in its Mojo Grade from Hold to Sell as of 9 March 2026, reflecting growing concerns over price attractiveness amid subdued financial performance and sector headwinds.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive rating to a fair valuation. Despite this adjustment, the company’s financial performance and market returns continue to pose concerns for investors, reflected in its downgraded Mojo Grade to Sell. This article analyses the valuation changes, compares Nureca’s metrics with peers, and assesses the implications for investors amid a challenging market backdrop.

Nureca Ltd, a player in the healthcare services sector, has seen its investment rating downgraded from Hold to Sell as of 9 March 2026. This shift reflects a combination of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly financial results. The company’s current Mojo Score stands at 34.0, with a Sell grade, marking a significant change in investor sentiment.